Learn how to translate yeast surface display outputs (affinity, palapala ʻāina epitope, ʻoki ʻoki) into actionable peptide synthesis specifications.
Unuhi i nā hua hōʻike Yeast i nā kikoʻī Peptide Synthesis
Hōʻike hū hū (YSD) ʻo ia kekahi o nā papa hana kiʻekiʻe loa no ka ʻike ʻana i ka binder, hoʻopaʻa pili pili, a me ka palapala ʻāina epitope maikaʻi. Ma ka hoʻohui ʻana i nā ʻano like ʻole o ka waihona pūmua me ka protein paʻa paʻa hū Aga2p, Hiki i nā hui ʻike ke nānā i nā miliona o nā ʻano like ʻole me ka hoʻohana ʻana i ka fluorescence-activated cell sorting (FACS) e hoʻokaʻawale i nā paʻi me ka picomolar i nā pili pili nanomolar.
Eia naʻe, Hiki mai kahi bottleneck nui i ka wā e hoʻololi ai i kēia mau hits mai nā hui hōʻike biological i nā hui peptide synthesis kemika. He kaʻina i hoʻopaʻa paʻa i ka ʻili o ʻO Saccharomyces cerevisiae hana pinepine ʻole ʻia e like me kahi peptide synthetic kūʻokoʻa. Me ka ʻole o ka unuhi ʻōlelo paʻakikī, Hoʻopilikia pinepine ʻia nā peptides kūʻokoʻa i ka nalowale ʻole o ka pilina paʻa, hiki ole ke hooheheeia, ka hoʻohui ʻana i ka wā paʻa-phase peptide synthesis (SPSS), a i ʻole nā mea ʻawaʻawa ola i hoʻokumu ʻia e nā counterions cleavage koena.
No ka hoʻopau ʻana i ka hoʻāʻo a me ka hewa i waena o ka ʻike biology a me nā hui hana, Pono nā alakaʻi ʻike e unuhi i nā heluhelu hōʻike olaola i loko o nā pepa hana kemika. I ka manawa ka unuhi ʻana i ke kaʻina hana kiʻekiʻe i nā peptides mākaukau lab kino, pono nā hui noiʻi e hahai i kahi ʻenehana hana ʻenehana 5-step e palapala i nā ʻāpana hōʻike pololei i nā kikoʻī hana synthetic.
ʻanuʻu 1: Hoʻokaʻawale i nā hale hōʻikeʻike hū e hoʻokaʻawale i ke kaʻina kūʻokoʻa
ʻO ka hana mua i ka unuhi ʻana i ka ʻikepili hōʻike hū ka helu ʻana i nā ʻokoʻa like ʻole ma waena o nā fusion cell-surface a me nā molekole synthetic soluble..
I nā ʻōnaehana hōʻike hū maʻamau, Hōʻike ʻia nā peptides moho e like me nā protein fusion i hoʻopili ʻia i ka subunit Aga2p ma o nā mea hoʻopili maʻalahi - ka mea maʻamau. (GGGGS)₃ a i ʻole (GGGS)₂ nā kaʻina—a hoʻopili ʻia e nā hōʻailona ʻike e like me c-myc a i ʻole HA. Hoʻopaʻa ka heleuma o ka paia i ke kūʻokoʻa conformational a me ka masks terminal charges i loaʻa ʻole i loko o kahi kaulahao peptide manuahi..
Ki Takeaway: Mai hoʻohui i kahi hōʻike hū me ka hoʻohana ʻana i nā huaʻōlelo makaʻala pololei mai ke kaʻina o ka hanauna e hiki mai ana (NGS). ʻO ka mea hoʻopili maʻalahi, hōʻailona epitope, a me nā wahi hoʻopili Aga2p pono e hoʻopau ʻia, a pono e ho'ākāka 'ia ke kemika ho'opi'i hope.
Hoʻolālā Kemika Capping Terminal
Hoʻopau maoli ʻia kahi peptide manuahi i hoʻopaʻa ʻia e SPPS me kahi amine N-terminal i hoʻopiʻi maikaʻi ʻia. (-NH₃⁺) a me ka carboxylate C-terminal i hoʻoili ʻole ʻia (-COO⁻). Inā hoʻopili ka hana hōʻike kumu i ka peptide ma o kāna C-terminus iā Aga2p, ka C-terminal carboxyl pūʻulu i hana mua i loko o ka neutral amide paʻa.
N-Terminal Acetylation (N-Ac): Hoʻokaʻawale i ka uku N-terminal e hoʻohālike i kahi iwi hope peptide mau a i ʻole ʻāpana protein i loko.
C-Terminal Amidation (C-NH₂): Hoʻololi i ka ʻakika carboxylic hope i loko o kahi pūʻulu carboxamide i kau ʻole ʻia, hoʻohālikelike i ka paʻa amide i ka wā o ka hōʻike hū.
Inā ʻaʻole e hilinaʻi ʻia ka pilina pili i nā pilina electrostatic me nā huaʻōlelo manuahi maoli, ʻO ka kikoʻī paʻamau no nā analog synthetic i loaʻa mai nā puka lou i loko N-acetylation a me C-amidation.
Hiki i ka hōʻike hū ke hiki i ka palapala ʻāina wikiwiki o ka hoʻopaʻa ʻana i nā ʻāina ikaika ma o ka scan mutational hohonu (DMS), ka nānā ʻana alanine, a me nā hale waihona puke nested truncation. Pono ka unuhi ʻana i kēia mau heluhelu e hoʻokumu i nā palena kaʻina akaka no ka synthesis kemika.
| Hana Hōʻikeʻike YSD: [Aga2p] — (Mea hoʻopili) — [ Aia ʻo A | ʻO ke kumu kumu liʻiliʻi | Aia ʻo B ] — [Tag] | kikoʻī | | — | — | | Hana Hōʻikeʻike YSD | [Aga2p] — (Mea hoʻopili) — [ Aia ʻo A | ʻO ke kumu kumu liʻiliʻi | Aia ʻo B ] — [Tag] | | Pākuʻi SPPS Chemical | [ Kāpena N-Kauā ] — [ Kaʻina kumu ] — [ Kāpena C-Term ] |
1. ʻIke ʻikepili ʻo Alanine e ʻike ai i nā wahi wela
ʻIke ʻia ka ʻimi ʻana ʻo Alanine i nā koena hoʻokahi kahi e alakaʻi ai ke pani ʻana i ka nalowale nui o ka nakinaki manuahi (ΔΔG > 1.0 kcal/mol).
Wahi Wela Koʻikoʻi: Pono e noho ʻokoʻa i ka ʻōlelo kikoʻī synthesis.
Nā kūlana hoʻomanawanui: Hiki ke hoʻohana ʻia nā kūlana koʻikoʻi ʻole i ʻike ʻia e ka ʻae alanine ma hope no ka hoʻololi ʻana i ka solubility, hōʻailona isotope, a i ʻole nā mea hoʻololi amino acid non-canonical me ka ʻole o ka hoʻopili ʻana i ka pilina.
2. Hoʻopaʻa palapala ʻāina ʻo Truncation Boundary
Hoʻokumu ʻia nā hale waihona puke ʻokiʻoki ʻia ma FACS i ke kumu paʻa liʻiliʻi. Inā ʻoki ʻia i ke koena i ke kumu o ka hāʻule ʻana o ka hōʻailona fluorescence FACS i ka wā e ʻoki ana i ke koena i-1 paʻa paʻa, koena i wehewehe i ka palena kino koʻikoʻi o ka peptide.
E hōʻoia i ka holomua hoʻokolohua, pono e kuhikuhi i ka pōkole hana a ʻO ka papa 3-peptide i hoʻopaʻa ʻia:
Kaʻina kumu liʻiliʻi: ʻO ka ʻāpana hoʻomau pōkole loa e hoʻopaʻa i ka hana hoʻopaʻa ʻana e like me nā palena ʻoki.
N-Hoʻonui ʻia: kumu liʻiliʻi + 2 i 3 nā koena ʻaoʻao N-terminal no ka mālama ʻana i ka paʻa o ka hale lua.
C-Hoʻonui ʻia: kumu liʻiliʻi + 2 i 3 nā koena ʻaoʻao C-terminal no ka pale ʻana i ka hopena.
ʻanuʻu 3: E ho'ēmi i ka Synthesis Bottlenecks a me ka Hydrophobic Aggregation
ʻO nā mea hoʻopaʻa hydrophobic i hoʻokaʻawale ʻia mai nā hale waihona puke hōʻike hū pinepine e hōʻike pinepine i nā pilikia synthetic i ka wā o ka Fmoc solid-phase peptide synthesis.. I ka wā SPPS, ʻO nā kaʻina hydrophobic e hoʻohana i nā hale β-sheet intermolecular ma ka resin, ke kumu o ka hoʻopili ʻana i ka "sequence paʻakikī"., hoʻopau ʻole ʻia, a me nā mea haumia holoi ʻoki ʻia.
⚠️ ʻŌlelo Aʻo: Hiki ke hōʻuluʻulu piha kahi kaʻina i hōʻike maikaʻi ʻia ma nā pūnaewele hū ke hoʻopaʻa ʻia i loko o ka wai paʻa e like me ka peptide synthetic.. E noʻonoʻo mau i ka hydrophobicity ma mua o ke kau ʻana i kahi kauoha synthesis.
Nā Hoʻololi Kemika a me nā Tags Solubility
Ke wānana ka nānā ʻana o ke kaʻina hana i ka propensity aggregation kiʻekiʻe (e.g., nā kaʻina waiwai i Val, Me, Leu, Ua haʻi aku ʻo Phe, aiʻole Trp), Pono e hoʻokomo i ka pōkole synthesis i nā hoʻolālā hoʻoheheʻe kemika.
[ Hydrophobic Core Motif ] + [ Tag hoʻoheheʻe / Mea hoʻopili ]
Hōʻailona hoʻoheheʻe Terminal: Hoʻohui i kahi tri-lysine (K₃ a i ʻole K₄) a i ʻole tri-glutamate (E₃ a i ʻole D₃) hōʻailona ma kahi palena paʻa ʻole (hoʻoholo ʻia e ka palapala ʻāina epitope) hoʻomaikaʻi nui i ka hoʻoheheʻe wai me ka hoʻololi ʻole i ka paʻa paʻa.
Nā loulou PEG: Hoʻokomo ʻana i nā mea hoʻopili polyethylene glycol monodisperse pōkole (PEG₂ a i ʻole PEG₄, e.g., 8-amino-3,6-dioxaoctanoic acid) ma waena o ka peptide kumu a me kekahi hōʻailona hana e hāʻawi i ka hoʻokaʻawale spatial a pale i ka pale steric.
ʻO nā dipeptides hoʻohuli: No ka hoʻokō synthesis, e noi ana i ka pseudoproline dipeptides (e.g., Fmoc-Ser(tBu)-Thr(ΨMe,Mepro)-OH) i ka wā SPPS e hoʻopau i ka hoʻokumu ʻana i ka β-sheet i hoʻopaʻa ʻia i ka resin a hoʻonui nui i nā hua hui lōʻihi..
Ke koi nā kaʻina paʻakikī i ka kemika kiʻekiʻe, hoʻohana nā lawelawe hoʻololi peptide kūikawā e hōʻoia i nā hōʻailona solubilizing maʻamau, PEG spacers, a ua hoʻohui maikaʻi ʻia nā pāpale terminal i loko o ka hoʻolālā synthetic.
ʻanuʻu 4: E wehewehe i nā pae maʻemaʻe e pono ai a me nā hoʻololi hana
Pono e hoʻopili pololei ʻia nā koi hoʻomaʻemaʻe peptide me ka hoʻāʻo ʻana o ke ola o lalo. ʻO ke noi ʻana i nā pae hoʻomaʻemaʻe kūpono ʻole e pilikia paha i nā hopena hoʻokolohua hoʻopunipuni a i ʻole nā koina hana pono ʻole.
Hoʻohana i lalo
Pono ka maʻemaʻe HPLC
Ka Pahuhopu Pono
Pilikia Haumaemae Ki
Hoʻopaʻa paʻa mua (ELISA, Komohana)
≥ 85% i ≥ 90%
Hōʻoia kūpono kūpono
Nā kaʻina ʻoki liʻiliʻi
Kūlana Kinetics (SPR, LILO, ITC)
≥ 95%
ʻO ka ʻike mola pololei & K D ana
Hoʻopili pū i nā peptides holoi, hoʻohui ʻaoʻao kaulahao
Moʻomeheu Cell & Ma Vivo Assays
≥ 98%
Hoʻopau ʻana i nā mea ʻona kelepona & leo kūwaho
Koe TFA counterions, ʻimi i nā mea hoʻoheheʻe organik, nā endotoxins
Nā hoʻololi hana no ka mākaukau hoʻāʻo
Inā makemake ʻia ka peptide no ka hōʻoia orthogonal, Pono e hoʻokomo i nā lepili kikoʻī i ka wā SPPS ma mua o ka post-synthetically:
Biotinylation: Hōʻike ʻia me kahi N-terminal a i ʻole C-terminal PEG₂ spacer e hōʻoia i ka hoʻopaʻa ʻole ʻia ʻana i ka Surface Plasmon Resonance i uhi ʻia e streptavidin (SPR) chips a i ʻole biolayer interferometry (LILO) nā mea ʻike.
Hoʻopaʻa inoa Fluorescent: N-terminal FITC, 5-FAM, a i ʻole Cy5 lepili no ka polarization fluorescence pololei (FP) a i ʻole microscopy confocal.
ʻO ke poʻo i ka huelo a i ʻole ka Cyclization disulfide: Ke kāohi nei i ka maʻalahi o ka conformational no nā peptides i hoʻopaʻa ʻia i ʻike ʻia ma o nā hale waihona puke YSD waiwai nui o ka cysteine..
ʻanuʻu 5: E hoʻokumu i nā Koina Hoʻokuʻu Analytical a me nā kikoʻī Counterion
ʻO ka mea hope loa o kahi kikoʻī hana e wehewehe i nā pae hoʻokuʻu i koi ʻia ma ka Certificate of Analysis (COA). ʻAʻole lawa nā hōʻuluʻulu COA maʻamau maʻamau me ka ʻole o ka ʻikepili analytical maka no nā pipeline ʻike biopharma.
No ke kōkua: Pono mau i ka Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) anaana ana ma 214 nm ma kahi o 280 nm. ʻIke ʻia ma 214 Nm ka helu ʻana i nā paʻa amide backbone peptide, e hōʻoia i ka ʻike pono ʻia ʻana a me ka helu ʻana i nā haumia ʻaʻa ʻole.
1. ʻIkepili Nui (MS) ʻIkepili & Holoi Hoʻopili
Electrospray Ionization Mass Spectrometry (ESI-MS): Hōʻoia i ke kaumaha molekala monoisotopic i loko ± 0.02 Da o ka nuipa theoretical ([M+H]⁺).
LC-MS/MS Māhele Māhele: Pono no ka hōʻoia ʻana i ka paulele ʻana a me ka hoʻokaʻawale ʻana i nā haumia holoi hoʻokahi-amino-acid. (ΔM = -57 Da no Gly, -71 Da no Ala, -113 Da no Leo/Ile) ma muli o ka pau ʻole o ka hoʻohui ʻana.
2. Kūʻai Kūʻē: ʻO TFA i ka Acetate a i ʻole Chloride
I ka wā maʻamau Fmoc SPPS, ka wehe ʻana mai ka resin me ka trifluoroacetic acid (TFA) waiho i nā koena trifluoroacetate e pili ana me nā koena kumu (ʻO Arg, Lys, ʻO kāna) a me ka N-terminus. ʻO ke koena TFA he cytotoxic i ka moʻomeheu cell, hoʻololi i ka mana membrane, a keakea i ka paʻa o ka hoʻokumu ʻana.
No ka hoʻāʻo ʻana ma ke kelepona, nā haʻawina hoʻolālā, a i ʻole nā hiʻohiʻona holoholona in vivo, pono e wehewehe pono ka palapala hana hoʻololi kūʻē:
TFA i ka Acetate Exchange (CH₃COO⁻): Kūlana no ka moʻomeheu cell a me ke ʻano biophysical.
Hoʻololi ʻo TFA iā Chloride (Cl⁻): Manaʻo ʻia no nā ʻano hana physiological kūikawā a me nā haʻawina in vivo.
Peptide Synthetic (Mahope o ka mahele): [ Peptide-Lys⁺ ] · [ CF₃COO⁻ (TFA ʻona) ]
▼ (Kūʻai Kūʻē)
Ma Vivo Mākaukau Hoʻokuʻu Hua: [ Peptide-Lys⁺ ] · [ CH₃COO⁻ (Biocompatible Acetate) ]
Ma mua o ke kauoha ʻana i nā mea no nā haʻawina olaola, e hōʻoia i ka hāʻawi piha ʻana o kāu mea kūʻai synthesis analytical peptide characterization a me HPLC-MS hoʻokuʻu hoʻāʻo me nā chromatograms RP-HPLC i hana ʻole ʻia, nuipaʻa spectra, a me nā pae kuʻuna i hōʻoia ʻia.
Nānā Hiʻohiʻona: Ka unuhi ʻana i kahi Hydrophobic YSD Hit i loko o ka In Vivo-Ready Peptide
E hōʻike i ka hoʻolālā 5-step i ka hoʻomaʻamaʻa, e noʻonoʻo i kahi hoʻolaha ʻike ʻelele e huli ana i kahi pilina oncology receptor:
Heluhelu YSD: Ke Kaʻina Hana Hana Hou (NGS) ʻike ʻia kahi clone kiʻekiʻe (YSD-Binder-07) hōʻike ʻana i ka paʻa nanomolar ($K_D = 3.2 \kikokikona{ nM}$). ʻO ke kaʻina hana maka Aga2p-(GGGGS)₃-YPYDVPDYA-WVIWWL-EQKLISEEDL-C-Term.
ʻanuʻu 1 (ʻO ka wehe ʻana): Excision o ka heleuma Aga2p, (GGGGS)₃ mea hoʻopili, HA lā (YPYDVPDYA), a me ka inoa c-myc (EQKLISEEDL). Ua kapa ʻia ke kumu kumu N-Ac-WVIWWL-C-NH₂.
ʻanuʻu 2 (Na palena): Hōʻike ʻia ka palapala ʻāina Truncation i ka hexapeptide waena WVIWWL hāʻawi ʻia ke kumu hoʻopaʻa. Ua hana ʻia kahi papa 3-peptide: Koko liʻiliʻi (WVIWWL), N-Hoʻonui (GWVIWWL), a C-Hoʻonui (WVIWWLG).
ʻanuʻu 3 (Ka hoʻoheheʻe ʻana): Ma muli o ka hydrophobicity loa (helu GRAVY +2.1), he kahua C (PEG₂)-Lys-Lys-Lys Ua kuhikuhi ʻia ka hōʻailona solubility, a ua hoʻohana ʻia nā pseudoproline dipeptides i ka wā o Fmoc-SPPS e pale i ka hoʻohui resin.
ʻanuʻu 4 & 5 (Hoʻokuʻu i nā kikoʻī): Purity target set to $\ge 98%$ me ka TFA-to-acetate hoʻololi counterion ($< 0.1%$ TFA koena) no ka hoʻāʻo ʻana i ka apoptosis ma ke kelepona.
Ka hopena: ʻO ka analog unuhi (N-Ac-WVIWWL-(PEG₂)-KKK-NH₂) hoʻopaʻa ʻia ka pilina kiʻekiʻe ($K_D = 4.1 \kikokikona{ nM}$), hōʻike ʻia $>95%$ solubility i loko o ka PBS buffer ma 1 mM, a hōʻike i ka cytotoxicity kaʻa ʻole.
Hoʻoponopono pilikia & Nīnau pinepine (FAQ)
Q1: No ke aha e nalowale ai ka peptide i ka pilina paʻa ma hope o ka synthesized me ka ʻole o nā hōʻailona hōʻike?
Pane: Ma ka ili hu, ʻO ka hui pū ʻana o ka paia o ka Aga2p e hoʻopaʻa i ka entropy conformational a me nā masks charge repulsion. Loaʻa nā peptides kūʻokoʻa i ke kūʻokoʻa conformational ʻoi aku ka nui a me ka hoʻopiʻi ʻole ʻia. Inā wehe ʻia ʻo N- a i ʻole C-termini e moe kokoke ana i ka ʻeke paʻa, hiki i ka electrostatic repulsion ke hoemi i ka paa. Pa'amau mau i ka N-acetylation a me ka C-amidation ke 'ole ka ho'ā'o 'ana i ka hana e hō'oia i ka palena manuahi.
Q2: Pehea e hiki ai iā mākou ke pale i ka hōʻuluʻulu koʻikoʻi ma ka resin i ka wā SPPS no nā kaʻina YSD hydrophobic kiʻekiʻe?
Pane: Incorporate pseudoproline dipeptides at strategic intervals during SPPS to disrupt $\beta$-sheet secondary structures on the resin. Eia hou, hoʻopili i kahi C-terminal (PEG₂)-KKK ʻO ka hoʻoheheʻe ʻana i ka huelo i ka wā synthesis e pale i ka pilina pilikino ma luna o ka resin a me nā ʻano wai wai hope..
Q3: No ke aha he mea koʻikoʻi ka hoʻololi ʻana o ka counterion TFA ma mua o ka holo ʻana i nā hoʻāʻo e pili ana i ke kelepona?
Pane: Hoʻohana ʻo Fmoc cleavage maʻamau i ka trifluoroacetic acid, e waiho ana i ke koena trifluoroacetate counterions pili me na koena kumu (Lys, ʻO Arg, ʻO kāna). ʻO ke koena TFA ke kumu o ka hoʻopau ʻana o ka membrane cell a me ka cytotoxicity waho, e hāʻawi ana i ka heluhelu ʻana i nā mea ʻawaʻawa maikaʻi ʻole i nā bioassays. ʻO ka hoʻololi ʻana i ka TFA i ka acetate a i ʻole chloride e hōʻoia i ka biocompatibility.
E hoʻopololei i ka kamaʻilio ma waena o nā mea olaola ʻike a me nā mea hana kemika, E hoʻohana i kēia matrix unuhi maʻamau i ka wā e hana ai i nā kauoha kūʻai synthesis:
Hōʻike ʻia ka ʻili hū
Heluhelu olaola
Unuhi ʻia ʻo SPPS Specification
Hoʻolālā Hoʻolālā
ʻO ka hui ʻana o Aga2p-Linker-Peptide-Tag
Wehe iā Aga2p, mea hookui, a me nā hōʻailona epitope; e wehewehe i ka N-acetylation a me ka C-amidation
Hoʻopaʻa i nā wahi wela
ʻO Alanine scan ΔΔG > 1.0 kcal/mol
Hoʻokuʻu i nā kūlana koʻikoʻi; e kaha i nā kūlana koʻikoʻi ʻole no nā hōʻailona solubility
Nā palena ʻokiʻoki
Nalo o ka FACS paa i ke koena i
E hoʻolālā i ka pūnana pūnana: Koko liʻiliʻi, N-Hoʻonui, a me nā ʻano like ʻole C-Extended
Kaʻina Hydrophobicity
Maikaʻi Val/Ile/Leu/Phe kiʻekiʻe
Hoʻohui i ka hōʻailona K₃ C-terminal a i ʻole PEG₂ spacer; noi pseudoproline dipeptides ma SPPS
Hopena hoʻāʻo
Kinetics (SPR/BE) vs Moʻomeheu Cell
E wehewehe ≥ 95% maʻemaʻe no nā kinetics; ≥ 98% me ka hoʻololi ʻana o TFA-to-acetate no nā hoʻokolohua cell
ʻO ka unuhi ʻana i nā hua hōʻike hōʻike hū i loko o nā moho peptide ikaika e pono ai ka hoʻopaʻa lima ma waena o ka ʻike olaola a me ka hana kemika.. Ma ka wehewehe ʻana i nā palena ʻoki akaka, e hōʻike ana i nā kemika hoʻopaʻa hope kūpono, e hoʻoponopono mua i ka hydrophobicity, a me ka hoʻokumu ʻana i nā pae hoʻokuʻu analytical koʻikoʻi, Hiki i nā hui ʻike ke hoʻonui nui i nā helu kūleʻa synthesis a hoʻopau i nā lohi hoʻokolohua nui.
Inā makemake kāu hui i ka nui o ka nānā ʻana a i ʻole nā hui moho nui, ka hoʻohana ʻana i kahi hoʻohui kahua hana peptide synthesis maʻamau hāʻawi i ka ʻike loea, hiki ke hoʻololi paʻakikī, a Papa 100 ʻO ka hōʻoia maikaʻi o ka lumi maʻemaʻe pono e hoʻololi i nā hōʻike hōʻike i nā moho biopharma i hoʻopaʻa ʻia.
Kaʻina hana R&D a me ka Mea Hana HanaKaʻike kumu: Hoʻonui kaʻina hana, kemika ʻōmaʻomaʻo, hoʻomaikaʻi maikaʻi, Hoʻokō ka hana GMP.
Pilikino: He loea ʻo Jinling Liu i ka unuhi ʻana o nā lāʻau peptide mai ka pālākiō keʻena (pae milligram) i ka hana pāʻoihana (pae kilokani). Ua kūpaʻa ʻo ia i ka hōʻemi nui ʻana i nā kumukūʻai hana peptide a me ka hōʻemi ʻana i ka pollution kaiapuni ma o ka hoʻonui ʻana i nā kūlana cleavage., ka hoʻomaikaʻi ʻana i nā lakio o nā condensation reagents, a me ka hoʻolauna ʻana i ka ʻenehana synthesis kahe mau. Ua alakaʻi ʻo ia i ka optimization o nā papahana peptide he nui, ka loaʻa ʻana o ke kumu kūʻai haʻahaʻa, hoʻomaʻemaʻe kiʻekiʻe ma ka pālākiō 100-kilogram.
🟢 Online · Pane i loko o 24h · Peptide Synthesis & CRO
MC
Aloha 👋 Welina mai iā MOL Changes
E haʻi mai iā mākou i kāu mea e pono ai - sequence, ka maemae, ka nui a i ʻole assay - a e pane kā mākou hui synthesis me kahi ʻōlelo kikoʻī i loko o hoʻokahi lā ʻoihana. ʻAʻole pono ka uku pūnaewele.